1 reports of this reaction
1.1% of all GUAIFENESIN AND PSEUDOEPHEDRINE HCL reports
#20 most reported adverse reaction
CHOLELITHIASIS is the #20 most commonly reported adverse reaction for GUAIFENESIN AND PSEUDOEPHEDRINE HCL, manufactured by H E B. There are 1 FDA adverse event reports linking GUAIFENESIN AND PSEUDOEPHEDRINE HCL to CHOLELITHIASIS. This represents approximately 1.1% of all 92 adverse event reports for this drug.
Patients taking GUAIFENESIN AND PSEUDOEPHEDRINE HCL who experience cholelithiasis should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
CHOLELITHIASIS is a less commonly reported adverse event for GUAIFENESIN AND PSEUDOEPHEDRINE HCL, but still significant enough to appear in the safety profile.
In addition to cholelithiasis, the following adverse reactions have been reported for GUAIFENESIN AND PSEUDOEPHEDRINE HCL:
The following drugs have also been linked to cholelithiasis in FDA adverse event reports:
CHOLELITHIASIS has been reported as an adverse event in 1 FDA reports for GUAIFENESIN AND PSEUDOEPHEDRINE HCL. This does not prove causation, but indicates an association observed in post-market surveillance data.
CHOLELITHIASIS accounts for approximately 1.1% of all adverse event reports for GUAIFENESIN AND PSEUDOEPHEDRINE HCL, making it a notable side effect.
If you experience cholelithiasis while taking GUAIFENESIN AND PSEUDOEPHEDRINE HCL, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.